Zymeworks Inc (ZYME) has issued an announcement.
Zymeworks Inc. has announced the immediate removal of Dr. Christopher Astle as Senior Vice President and Chief Financial Officer. Kenneth Galbraith, the current Chair of the Board, President, and CEO, has been appointed as the interim CFO. Galbraith brings over 35 years of experience in the biotech and healthcare sectors and will maintain his existing roles while taking on the CFO duties. The company is actively searching for a new CFO, and there are no conflicts of interest or family relations influencing Galbraith’s interim appointment.
For a thorough assessment of ZYME stock, go to TipRanks’ Stock Analysis page.
